TAF10: A Potential Drug Target and Biomarker for Transcription Initiation Factor TFIID 30 kD Subunit

Target Name: TAF10

NCBI ID: G6881

TAF10

TAF10: A Potential Drug Target and Biomarker for Transcription Initiation Factor TFIID 30 kD Subunit

Abstract:
Transcription initiation factor TFIID 30 kD subunit (TAF10) is a key regulator of gene expression and has been implicated in various diseases. Although numerous studies have investigated TAF10's function, its potential as a drug target or biomarker remains poorly understood. In this article, we will summarize the current knowledge about TAF10, highlight its potential as a drug target, and discuss its potential as a biomarker for various diseases.

Introduction:
Transcription initiation factor TFIID 30 kD subunit (TAF10) is a protein that plays a crucial role in regulating gene expression. It is a key component of the TFIID complex, which is responsible for initiating the transcription process by binding to specific DNA sequences. TAF10's function is highly conserved across various species, and its presence is essential for the regulation of gene expression in all organisms.

Potential Drug Target:
The potential drug targets for TAF10 are numerous and diverse. One of the most significant targets is the regulation of cancer progression. TAF10 has been shown to play a crucial role in the regulation of cell cycle progression and has been implicated in the development and progression of various cancers. Additionally, TAF10 has also been linked to the regulation of cell survival and has been shown to promote the survival of cancer cells. Therefore, TAF10 may be an attractive drug target for cancer treatment.

Potential Biomarkers:
TAF10 has also been suggested as a potential biomarker for various diseases. The regulation of TAF10 activity has been implicated in the development of various diseases, including neurodegenerative diseases, autoimmune diseases, and diseases associated with inflammation. Therefore, TAF10 may be a valuable biomarker for the diagnosis and management of such diseases.

Structure and Function:
The structure of TAF10 is well conserved across various species and has been studied extensively. TAF10 is a 21 kD protein that contains a unique N-terminal domain, a central transmembrane domain, and a C-terminal domain. The N-terminal domain is known as the TAF10-specific domain and is responsible for TAF10's unique function as a transcription initiation factor. The C-terminal domain is involved in TAF10's stability and has been shown to play a role in TAF10's regulation of gene expression.

The function of TAF10 is highly regulated by various factors, including the concentration of transcription factors, the availability of resources, and the presence of inhibitors. TAF10 has been shown to interact with various transcription factors, including histones, RNA-binding proteins, DNA-binding Protein etc. The interaction of TAF10 with these transcription factors allows it to regulate the expression of target genes.

Mutations in TAF10 have been observed in various diseases, including cancer and neurodegenerative diseases. These mutations have led to the loss of TAF10's function and have led to the development of various diseases. Therefore, studying the function of TAF10 is essential for the development of new therapeutic strategies for diseases associated with TAF10 dysfunction.

Conclusion:
In conclusion, TAF10 is a protein that plays a crucial role in regulating gene expression and has been implicated in various diseases. Its function as a transcription initiation factor makes it an attractive target for drug development, and its potential as a biomarker for various diseases makes it a valuable tool for the diagnosis and management of such diseases. Further research is necessary to fully understand the function of TAF10 and its potential as a drug target and biomarker.

Protein Name: TATA-box Binding Protein Associated Factor 10

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF10 is also component of the PCAF histone acetylase complex, the TATA-binding protein-free TAF complex (TFTC) and the STAGA transcription coactivator-HAT complex (PubMed:18206972, PubMed:11564863, PubMed:9885574, PubMed:10373431, PubMed:12601814). May regulate cyclin E expression (By similarity)

The "TAF10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets